Contents: Substance Use Disorder: Clinical Expert Series
Metz, Torri D. MD, MS; Borgelt, Laura M. PharmD
Denver Health and Hospital Authority, Denver, and the University of Colorado School of Medicine and the University of Colorado Skaggs School of Pharmacy, Aurora, Colorado.
Corresponding author: Torri D. Metz, MD, MS, 30 North 1900 East, 2B200, Salt Lake City, UT 84132; email: [email protected].
Dr. Metz was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development under award number 5K12HD001271-18. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Financial Disclosure Dr. Borgelt received grant funding from the Colorado Department of Public Health and Environment (CDPHE) for a study evaluating the use of cannabidiol for the treatment of refractory pediatric epilepsy. Additionally, she has provided continuing education for pharmacists through PharmCon, Inc and served on seven different working groups for the Colorado Department of Revenue and CDPHE regarding use of cannabis and patient safety. Dr. Metz did not report any potential conflicts of interest.
Continuing medical education for this article is available at https://links.lww.com/AOG/B149.
The authors thank Amanda Allshouse for creating Figure 3. Ms. Allshouse is supported by the Department of Obstetrics and Gynecology at Denver Health and Hospital Authority.
Each author has indicated that she has met the journal's requirements for authorship.